You have 9 free searches left this month | to do more

umbralisib

Umbralisib is a drug used to treat Chronic Lymphocytic Leukemia, Follicular Lymphoma, Small Lymphocytic Lymphoma, and other conditions. Umbralisib is being actively studied in 14 studies and prior, has been studied in 1.

Top SponsorsTop SitesTop Investigators
TG Therapeutics, Inc.TG Therapeutics Investigational Trial SiteAmitkumar Mehta, MD
City of Hope Medical CenterCity of Hope Medical CenterJacob Soumerai, MD
ADC Therapeutics S.A.Ohio State University Comprehensive Cancer CenterJennifer R. Brown, MD, PhD
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Suspended
  • Hodgkin's Lymphoma
  • Pembrolizumab
  • Umbralisib
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-08
Mar 8, 2022
C
Not yet recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Duarte, California
    City of Hope Medical Center
2022-02-16
Feb 16, 2022
U
Suspended
  • Marginal Zone Lymphoma
  • Follicular Lymphoma
  • Aurora, Colorado
    University of Colorado Hospital
2022-02-22
Feb 22, 2022
W
Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • New York, New York
    Weill Cornell Medicine
2022-03-29
Mar 29, 2022
U
Recruiting
  • Mantle Cell Lymphoma
  • Birmingham, Alabama
    University of Alabama at Birmingham
2021-09-08
Sep 8, 2021
T
Active, not recruiting
  • Follicular Lymphoma
  • Small Lymphocytic Lymphoma
  • Fort Myers, Florida
  • +2 more
2022-03-22
Mar 22, 2022
T
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin Lymphoma
  • Chicago, Illinois
  • +2 more
2022-03-22
Mar 22, 2022
T
Completed
  • Chronic Lymphocytic Leukemia
  • Richter Syndrome
  • Umbralisib
  • +2 more
  • New York, New York
  • +3 more
2021-12-21
Dec 21, 2021
H
Suspended
  • Chronic Lymphocytic Leukemia
  • Umbralisib
  • Tampa, Florida
    H. Lee Moffitt Cancer Center & Research Institute
2022-02-07
Feb 7, 2022
C
Recruiting
  • Mantle Cell Lymphoma
  • Duarte, California
    City of Hope Medical Center
2021-08-10
Aug 10, 2021
T
Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • Umbralisib
  • Washington, District of Columbia
  • +3 more
2022-03-22
Mar 22, 2022
M
Recruiting
  • Lymphoma
  • +6 more
  • Boston, Massachusetts
  • +1 more
2020-08-31
Aug 31, 2020
T
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Birmingham, Alabama
  • +49 more
2022-03-22
Mar 22, 2022
Y
Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2022-02-23
Feb 23, 2022
J
Recruiting
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Boston, Massachusetts
  • +2 more
2021-05-10
May 10, 2021
T
Recruiting
  • Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • East Melbourne, Victoria, Australia
  • +7 more
2022-03-22
Mar 22, 2022
T
Active, not recruiting
  • Diffuse Large B-Cell Lymphoma
  • +4 more
  • Ublituximab
  • +2 more
  • Birmingham, Alabama
  • +167 more
2022-03-22
Mar 22, 2022
N
Suspended
  • Grade 1 Follicular Lymphoma
  • +4 more
  • Bendamustine Hydrochloride
  • +7 more
  • Anchorage, Alaska
  • +422 more
2022-04-05
Apr 5, 2022